phrykt

Apyx Medical Corp (APYX): who owns it and who trades it

As of Nov 16, 2026, no open-market insider purchases or sales of APYX were reported in the last 12 months. 2 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Apyx Medical

From the latest filings

Overall: more selling than buying. Famous investors mostly sold. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns APYX

68 funds and institutions reported APYX shares worth $111M at the end of Q2 2026, about 59% of the company. The largest holder is Nantahala Capital Management, LLC with 15.6%.

Funds and institutions (13F) 59%Everyone else 41%

10 largest owners, by share of the company

Nantahala Capital Management, LLC15.6%
Royce & Associates LP7.8%
Archon Capital Management LLC6.3%
Vanguard Capital Management LLC3.7%
Essex Investment Management Co LLC2.7%
AIGH Capital Management LLC2.7%
Silverberg Bernstein Capital Management LLC2.5%
Commonwealth Equity Services, LLC1.6%
Horizon Kinetics Asset Management LLC1.4%
BlackRock, Inc.1.3%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Nantahala Capital Management, LLC6.54M15.64%$29.4M+90%
Royce & Associates LP3.27M7.83%$14.7M+25%
Archon Capital Management LLC2.64M6.32%$11.9M-5%
Vanguard Capital Management LLC1.53M3.67%$6.9M-1%
Essex Investment Management Co LLC1.14M2.72%$5.1M+26%
AIGH Capital Management LLC1.13M2.70%$5.1M+2%
Silverberg Bernstein Capital Management LLC1.04M2.49%$4.7M-0%
Commonwealth Equity Services, LLC649,0611.55%$2.9MNo change
Horizon Kinetics Asset Management LLC585,0001.40%$2.6M-5%
BlackRock, Inc.560,9861.34%$2.5M+6%
Renaissance Technologies LLC554,2781.33%$2.5M+83%
Taylor Frigon Capital Management LLC413,6020.99%$1.9M-0%
Geode Capital Management, LLC400,6000.96%$1.8M+2%
Legato Capital Management LLC382,7620.92%$1.7M+36%
Sei Investments Co281,0290.67%$1.3M-53%
Huntleigh Advisors, Inc.263,2310.63%$1.2M+7%
Millennium Management LLC242,6630.58%$1.1M-7%
Marshall Wace, LLP236,4660.57%$1.1M+282%
Vanguard Fiduciary Trust Co224,0210.54%$1M+11%
Susquehanna International Group, LLP216,2630.52%$971K-19%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

No APYX insider reported an open-market purchase or sale in the last 12 months.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
–
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

APYX short interest

Low short interest. 0.6% of APYX shares are sold short: about 1 share in 172. Over the last 12 reports the number of shares short went up 47%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 245,424 APYX shares were sold short, 0.6% of the shares outstanding, up 14.8% from the report before. At the average daily volume of 118,106 shares, buying them all back would take about 2.1 trading days (days to cover).

Shares short, % of all shares

0.58%May 15Oct 300.68%

Days to cover

2.1May 15Oct 305.2

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 2026245,4240.58%+15%118,1062.1
Oct 15, 2026213,7300.51%+3%118,9151.8
Sep 30, 2026206,8250.49%-5%176,5601.2
Sep 15, 2026218,0490.52%+6%88,4932.5
Aug 31, 2026205,1970.49%-11%160,8141.3
Aug 14, 2026230,3540.55%-14%154,2431.5
Jul 31, 2026267,1450.64%+6%56,9504.7
Jul 15, 2026251,6680.60%+42%64,8143.9
Jun 30, 2026177,2780.42%+27%147,4731.2
Jun 15, 2026139,6640.33%-34%200,0161.0
May 29, 2026211,9480.51%+27%115,6231.8
May 15, 2026167,4460.40%-24%351,0361.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Apyx Medical company events

Apyx Medical filed 14 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 5, 2026.

  1. Nov 5, 2026ResultsReleased financial results. Filing
  2. Sep 29, 2026AnnouncementApyx Medical Corporation issued a press release announcing the publication of new clinical data in Plastic and Reconstructive Surgery — Global Open highlighting results from a prospective clinical study evaluating the effects of Renuvion helium plasma radiofrequency technology on biological markers… Filing
  3. Aug 7, 2026LeadershipAs described under Item 5.07 of this Current Report on Form 8-K, Apyx Medical Corporation held its 2026 Annual Meeting of Stockholders, at which the Company’s stockholders approved the adoption of the Company’s 2026 Share Incentive Plan. Filing
  4. Aug 6, 2026ResultsReleased financial results. Filing
  5. Jul 24, 2026AnnouncementThe Board of Directors of Apyx Medical Corporation reconstituted the membership and chairs of its standing committees as described below. Filing
  6. Jun 17, 2026AgreementApyx Medical Corporation entered into a letter agreement with Stavros Vizirgianakis, the Chairman of the Company’s Board of Directors, in connection with Mr. Vizirgianakis’ appointment as Executive Chairman of the Board. Filing
  7. May 21, 2026AnnouncementApyx Medical Corporation issued a press release announcing the publication of a new clinical data in Aesthetic Surgery Journal Open Forum highlighting a promising approach to improving cellulite and skin laxity, two of the most common aesthetic concerns among women. Filing
  8. May 14, 2026AnnouncementApyx Medical Corporation issued a press release announcing the publication of a new retrospective investigator-initiated stud in Plastic and Reconstructive Surgery - Global Open . The study evaluated patient-reported outcomes following liposuction with and without helium plasma radiofrequency… Filing
  9. May 11, 2026AnnouncementApyx Medical Corporation issued a press release announcing it received expanded 510(k) clearance from the U.S. Food and Drug Administration clearance for the AYON Body Contouring System TM to include power liposuction. Filing
  10. May 7, 2026ResultsReleased financial results. Filing
  11. Mar 10, 2026ResultsReleased financial results. Filing
  12. Jan 12, 2026ResultsReleased financial results. Filing
  13. Dec 12, 2025RulesChanged its bylaws or articles. Filing
  14. Nov 19, 2025AgreementApyx Medical Corporation entered into an underwriting agreement with Lucid Capital Markets, LLC pursuant to which the Company will issue and sell to the Underwriter pursuant to the Underwriting Agreement 2,762,431 shares of common stock, par value $0.001 per share at an offering price of $3.62 and… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Apyx Medical financials

Famous investors that hold APYX

2 of the 50 well-known investors we track reported holding APYX in their latest 13F filing. The largest position is Jim Simons's, worth $939K.

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 2026383,395$939K0.0%-31%
Israel Englander · Millennium ManagementQ3 2026191,761$470K0.0%-21%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named APYX in the last 120 days.

FiledHolderFormStake
Oct 28, 2026Philotimo Fund, LP13G3.4%
Oct 28, 2026Philotimo Fund, LP13G3.4%

Questions about Apyx Medical Corp (APYX) stock

Who owns the most APYX stock?

The largest reported owner of Apyx Medical Corp (APYX) is Nantahala Capital Management, LLC, with 15.6% of the company. In total, 68 funds and institutions reported holding APYX at the end of Q2 2026, together about 59% of the shares. See the largest owners.

Are APYX insiders buying or selling?

No APYX insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.

What is the short interest in APYX?

As of Oct 30, 2026, 245,424 APYX shares were sold short, 0.6% of the shares outstanding, up 14.8% from the report before. At the average daily volume of 118,106 shares, buying them all back would take about 2.1 trading days (days to cover). See the history.

Which famous investors hold APYX?

2 of the 50 well-known investors we track reported APYX in their latest 13F filing, including Jim Simons, Israel Englander. The largest position is worth $939K. See all holders.

Executive pay

Apyx Medical's chief executive was paid a total of $1.2M for the year ended Dec 31, 2025, up 26% from $976K the year before. In the last 12 months, Apyx Medical's executives and directors bought no stock on the open market and sold none.

Chief executive, total pay$1.2MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$2.1MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$642KThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.